---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-080013"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T09:57:13.843766+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Iovance prices $150M public offering of 20M shares at $7.50; underwriter option for 3M more

## Summary
- Priced 20M shares at $7.50/share for gross proceeds of $150M; net proceeds ~$140.2M.
- Underwriters granted 30-day option for up to 3M additional shares; total offering up to 23M shares.
- Proceeds to fund lifileucel commercial launch prep, manufacturing facility, and clinical programs.
- Offering led by Goldman Sachs & Co. LLC and Jefferies LLC; expected to close July 13, 2023.
- Executive officers and directors entered 90-day lock-up agreements on stock sales.

## SEC filing metadata
- accession: 0001104659-23-080013
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923080013/0001104659-23-080013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923080013/tm2320915d5_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-080013
- JSON: https://secwatch.observer/filing/0001104659-23-080013.json
- Plain text: https://secwatch.observer/filing/0001104659-23-080013.txt

## Key facts
- Material Agreements
  IOVANCE BIOTHERAPEUTICS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC and Jefferies LLC valued at up to 23,000,000 shares of common stock at $7.50 per share (effective 2023-07-10).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC and Jefferies LLC
  - Value: up to 23,000,000 shares of common stock at $7.50 per share
  - Effective: 2023-07-10
  source text: On July 10, 2023, Iovance Biotherapeutics, Inc. (the “Company”) entered in an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC and Jefferies LLC (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell up to 23,000,000 shares of common stock (the “Shares”), which includes 3,000,000 shares (the “Optional Shares”) that may be sold pursuant to a 30-day option to purchase additional shares granted to the Underwriters (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923080013/0001104659-23-080013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.